We caught up with Tanya Simuni (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) to discuss the use of venglustat in the treatment of patients with Parkinson’s Disease, and the Phase 2 MOVES-PD study results.
Part 2 of our discussion can be viewed here.
The abstract entitled ‘Venglustat in Parkinson’s Disease Patients with a GBA Mutation: Results from Part 2 of the Phase 2 MOVES-PD Trial’ was presented at The 15th International Conference for Alzheimer’s & Parkinson’s Diseases (Virtual), March 8-14, 2021.
Questions:
- What was the rationale for the use of venglustat in the treatment of patients with Parkinson’s Disease (PD)? (0:14)
- Following the recent failure of the MOVES-PD trial, what are your thoughts on the future use of GBA-targeting treatments in PD? (1:35)
- What other novel therapeutic approaches seem promising? (4:54)
Disclosures: Tanya Simuni, MD has served as a consultant for Acadia, Denali, General Electric (GE), Neuroderm, Sanofi, Sinopia, Sunovion, Roche, Takeda, MJFF and Voyager. Dr. Simuni served on the ad board for Acadia, Denali, General Electric (GE), Sunovian, Roche. Dr. Simuni has served as a member of the scientific advisory board of Neuroderm and Sanofi. Dr. Simuni has received research funding from Biogen, Roche, Neuroderm, Sanofi, Sun Pharma, Amneal, Prevail, UCB, NINDS, MJFF, Parkinson’s Foundation.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AD/PD Virtual 2021.
